Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Protein Design Labs acquires ESP Pharma for $514mm

Executive Summary

Protein Design Labs (monoclonal antibodies) has agreed to acquire ESP Pharma (specialty drugs) for $300mm in cash and 8.87mm PDL common shares (valued at about $175mm). PDL will also assume $14mm of ESP's debt.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register